• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

HYDERABAD: Aurobindo Pharma Ltd has obtained a tentative approval from the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of Setraline Hydrochloride in tablets of 25 mg (base), 50 mg (base) and 100 mg (base).

In a press release here on Tuesday, the company said it would be able to market the product in the US market after the expiry of the Setraline Hydrochloride product patent and also upon final approval from the USFDA.

Aurobindo Pharma said the tentative approval is important for the company in terms of its R&D capabilities. The approval terms the generic drug product to be bio-equivalent and having the same therapeutic effect to the innovator product - Zoloft of Pfizer Inc - the release said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
OTS for Hyderabad Flextech

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line